Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
103 hedge funds and large institutions have $94M invested in Surface Oncology, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 23 closing their positions.
128% more call options, than puts
Call options by funds: $524K | Put options by funds: $230K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 32
3% less funds holding
Funds holding: 106 → 103 (-3)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
20% less capital invested
Capital invested by funds: $118M → $94M (-$24M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$16.3M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$8.06M |
| 3 |
Renaissance Technologies
New York
|
+$2.1M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.28M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.49M |
| 2 |
O
OrbiMed
New York
|
-$2.24M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$1.57M |
| 4 |
GCM
Goldstream Capital Management
Central,
Hong Kong
|
-$1.15M |
| 5 |
SO
STRS Ohio
Columbus,
Ohio
|
-$638K |
SURF Hedge Fund Activity: Q1 2022 in Review
103 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q1 2022, worth a combined $94M — down 20% from $118M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SURF and 20 opened new positions — a net loss of 3 holders — while 32 trimmed existing stakes and 32 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $16.3M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $2.49M sold.
- 103 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q1 2022, down from 106 in Q4 2021.
- Funds reported $94M of Surface Oncology, Inc. Common Stock stock for Q1 2022, down 20% quarter-over-quarter.
- 20 funds opened new Surface Oncology, Inc. Common Stock positions in Q1 2022 and 23 closed out, a net change of -3 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q1 2022 was EcoR1 Capital, an estimated $16.3M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q1 2022 was Farallon Capital Management, an estimated $2.49M sold.
Based on aggregated 13F filings for Q1 2022.